Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497691 | PMC |
| http://dx.doi.org/10.1002/ueg2.12624 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: A Multicenter Cohort Study.
Clin Gastroenterol Hepatol
November 2024
Department of Gastroenterology, Bicêtre University Hospital, AP-HP, Universite Paris Saclay, INSERM CESP, Le Kremlin Bicêtre, Le Kremlin Bicêtre, France.
Background & Aims: Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD). The aim of our study was to evaluate incident cancer rate (recurrence or new-onset cancer) in a cohort of patients with IBD with a history of breast cancer according to the subsequent IBD treatment provided.
Methods: A multicenter retrospective study included consecutive patients with IBD with prior breast cancer.
Association Between Vedolizumab Treatment and Arthritis/Arthralgia in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
J Gastrointestin Liver Dis
September 2024
Department of Gastroenterology, CliaGEN, Salvador, Bahia (BA), Brazil.
Background And Aims: Vedolizumab is a humanized gut selective drug that targets α4β7 integrin and has been used successfully in the treatment of inflammatory bowel disease (IBD). Pivotal studies have already demonstrated the drug's safety, but some real-life cohorts have shown an increase in arthralgia and arthritis in patients using vedolizumab. These findings raised the question of whether these joint symptoms are extraintestinal manifestations of IBD (since the drug acts only in the gut) or if they are associated with the use of vedolizumab.
View Article and Find Full Text PDFVedolizumab and new-onset spondyloarthritis: Debunking the myth.
United European Gastroenterol J
September 2024
Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Initiation of vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24-week study with imaging assessments.
United European Gastroenterol J
September 2024
Lawson Health Research Institute, London, Ontario, Canada.
Article Synopsis
- - The study aimed to explore if starting vedolizumab (a medication for inflammatory bowel disease) was linked to new-onset spondyloarthritis (SpA) in patients with IBD through clinical evaluations and MRIs.
- - 24 patients with active ulcerative colitis or Crohn's disease participated, with assessments made before starting treatment and at 8 and 24 weeks.
- - Results showed that none of the patients developed new forms of axial or peripheral SpA after 24 weeks, indicating that vedolizumab does not appear to trigger these conditions in either TNF inhibitor-naïve or experienced patients.
The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis.
J Gastroenterol Hepatol
September 2024
Department of Gastroenterology, First Hospital of China Medical University, Shenyang City, China.
Article Synopsis
- - The study investigates the effects of Vedolizumab (VDZ) on extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD), focusing on the resolution of pre-existing EIMs during treatment.
- - Out of 21 studies analyzed, 39% of VDZ-treated patients experienced resolution of their pre-existing EIMs, while rates of exacerbations and new onset EIMs were reported at 28% and 15%, respectively.
- - VDZ is effective for certain skin and joint-related EIMs, particularly erythema nodosum and arthritis, although some patients may see an increase in EIMs during treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!